Physician profile
Mathews Thomas
NPI 1689790586
$832.79
in general payments reported to CMS, 2019-2025
9 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.00 · 2022: $16.45 · 2023: $24.74 · 2024: $308 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792 · Education: $9.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.38 |
| Education | $9.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $247.01 | 2024-2025 | Abilify Mycite, Rexulti |
| Teva Pharmaceuticals USA, INC. | $215.36 | 2025 | Austedo Xr |
| Lundbeck LLC | $72.96 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.01 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $61.26 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $55.19 | 2021-2023 | Spravato |
| Livanova USA, INC. | $49.42 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Neurocrine Biosciences, INC. | $34.69 | 2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $27.89 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathews Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.